Last reviewed · How we verify
Bromday™
Bromday™, marketed by Sun Pharmaceutical Industries Limited, holds a position in the ophthalmic anti-inflammatory segment with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which supports its revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Bromday™ |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers (PHASE1, PHASE2)
- Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery (PHASE2)
- Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromday™ CI brief — competitive landscape report
- Bromday™ updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI